NTLA Q2 2017 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+40.7% YoY

Gross Profit

-$10M-163.1% margin

Operating Income

-$16M-270.7% margin

Net Income

-$16M-263.5% margin

EPS (Diluted)

$-0.45

QoQ Revenue Growth

-4.8%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$17M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$265M

Total Liabilities

$77M

Stockholders' Equity

$188M

Cash & Equivalents

$241M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$4M	+40.7%
Gross Profit	-$10M	-$3M	-199.9%
Operating Income	-$16M	-$7M	-130.6%
Net Income	-$16M	-$7M	-126.0%